Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC

December 30th 2021

Dr Bardia discusses the role of sacituzumab govitecan in the treatment of patients with metastatic triple-negative breast cancer, the influence of the National Comprehensive Cancer Network guidelines on treatment recommendations and sequencing in the second-line setting, and ongoing research with the agent in the neoadjuvant setting.

Practice-Changing Data From 2021 Sets Tone for New Year

December 29th 2021

Throughout 2021, investigators of several pivotal trials presented findings that may result in shifting standards for the treatment of patients across tumor types.

Abemaciclib Becomes First Agent of its Kind Approved for Adjuvant Treatment of Early Breast Cancer

December 28th 2021

Stephen Johnston, MD, PhD, provides insight on the effect the approval of the CDK4/6 inhibitor abemaciclib has for patients with early breast cancer and how it will advance investigative efforts in this space.

Pembrolizumab Combination Advances Standard of Care in TNBC

December 27th 2021

Peter Schmid, MD, PhD, discussed how this approval defines a new standard of care for patients with TNBC.

Coming Soon, HER2-Positive Breast Cancer: A Review of Data from the SABCS 2021 Virtual Meeting

December 23rd 2021

Virginia Kaklamani, MD, DSc, shares her excitement for an upcoming OncLive® "The TALK" program focusing on HER2-positive breast cancer updates from the SABCS 2021 Virtual Meeting.

Overview of Estrogen Receptor-Targeted Imaging

December 22nd 2021

Experts provide an overview of the imaging modalities that can detect estrogen receptor status in patients with breast cancer.

ER-Positive Breast Cancer and ER Testing Strategies

December 22nd 2021

Gary Ulaner, MD, PhD and Jeremy Force, DO review estrogen receptor (ER)-positive breast cancer and the various strategies available for diagnosing estrogen receptor (ER)-positive breast cancer.

Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer

December 20th 2021

Dr. Schwartzberg discusses the rationale to evaluate enobosarm in androgen receptor-positive, estrogen recepetor-positive advanced breast cancer, phase 2 data with the agent, and expectations for the ongoing phase 3 ARTEST trial in this population.

Leading Mass General Breast Surgeon Dr. Suzanne Coopey Joins AHN Cancer Institute

December 20th 2021

Breast surgeon Suzanne B. Coopey, MD, FACS, has joined Allegheny Health Network Cancer Institute, where she will serve as Director of the Breast Program at the soon-to-open AHN Wexford Hospital.

Coming Soon: THE TALK: Breast Cancer, A Review of Data from the SABCS 2021 Virtual Meeting

December 20th 2021

Investigators Parse a Crowded Third Line in Relapsed HER2-Positive Metastatic Breast Cancer

December 20th 2021

A panel of breast cancer experts shared their insights on 4 recently approved targeted therapies for patients with relapsed HER2-positive metastatic breast cancer.

Radical Sentinel Lymph Node and Axillary Lymph Node Dissection Can Negatively Affect Outcomes in Patients With Early-Stage Breast Cancer

December 16th 2021

Data presented from the INSEMA trial during the 2021 San Antonio Breast Cancer Symposium indicated that patients with early-stage breast cancer had better quality of life outcomes when forgoing a sentinel lymph node biopsy and axillary lymph node dissection. However, patients had improved arm symptoms and functioning with SLNB vs ALND.

Neratinib Combos Show Promise in HER2-Mutant Metastatic Breast Cancers

December 10th 2021

Neratinib (Nerlynx) induced positive overall response rates in patients with heavily pretreated hormone receptor–positive/HER2-negative, HER2-mutant metastatic breast cancer when combined with fulvestrant and trastuzumab, and also in patients with metastatic HER2-mutant triple-negative breast cancer when combined with trastuzumab.

Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer

December 10th 2021

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

AEs Related to Olaparib Treatment May Be Easily Mitigated in High-Risk Early Breast Cancer

December 10th 2021

Certain adverse effects associated with olaparib were minimal and resolved with appropriate management in patients with germline BRCA1/2 mutations in patients with high-risk, HER2-negative, early-stage breast cancer.

Likelihood of Pathologic CR After Neoadjuvant Chemo is Not Significantly Affected by Race in Breast Cancer

December 10th 2021

Pathologic complete response and event-free survival was not found to be significantly affected by race among patients with high-risk breast cancer who received neoadjuvant chemotherapy; however, disparities were observed among patients who did not achieve a pCR.

Dr. Ganz on the Quality of Life Results From the OlympiA Trial in BRCA-Mutated Breast Cancer

December 10th 2021

Patricia A. Ganz, MD, discusses the quality of life results from the phase 3 OlympiA trial in BRCA-mutated breast cancer.

Dr. Kruse on the Results of a Study Comparing Outcomes in Pleomorphic Vs Non-Pleomorphic Invasive Lobular Carcinoma

December 10th 2021

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Samuraciclib Plus Fulvestrant Improves PFS in Heavily Pretreated HR+ Breast Cancer

December 10th 2021

Fulvestrant plus the CDK7 inhibitor samuraciclib demonstrated encouraging efficacy in patients with hormone receptor-positive breast cancer who were heavily pretreated with CDK4/6 inhibitors.

Early Use of ctDNA Testing Can Identify Likelihood of Relapse in TNBC

December 9th 2021

Physicians treating patients with early-stage triple-negative breast cancer should employ circulating tumor DNA testing early and often, according to results from the phase 2 cTRAK TN trial.